A 6-month, Randomized, Active Comparator, Open-label, Multi-Center Study to Evaluate Patient Outcomes, Safety and Tolerability of Fingolimod (FTY720) 0.5 mg/Day in Patients With Relapsing Remitting Multiple Sclerosis Who Are Candidates for MS Therapy Change From Previous Disease Modifying Therapy

Aún no traducido Aún no traducido
Autores
Categoría Estudio primario
Registro de estudiosclinicaltrials.gov
Año 2011
Cargando información sobre las referencias
The purpose of this study is to evaluate the change in patient-reported treatment satisfaction after 6 months of treatment with fingolimod 0.5mg/day vs. DMT standard of care, using the global satisfaction subscale of the Treatment Satisfaction Questionnaire for Medication (TSQM-9).
Epistemonikos ID: 9eb193d40fc1f3ab6af6beca5f220b87127cc731
First added on: Oct 30, 2021